tradingkey.logo

Eli Lilly, Novo Nordisk shares fall after Trump targets weight-loss drugs

ReutersOct 17, 2025 8:24 AM

Shares of weight-loss drug developers Eli Lilly LLY.N and U.S.-listed shares of Novo Nordisk NOVOb.CO fall premarket

Trump said prices of weight-loss drugs, such as Novo's Ozempic, would be lowered

Lilly down 4.1% to $785.51, Novo falls 3.9% to $53.93; Novo's Denmark-listed shares down 6.3%

J.P.Morgan says, "we see President Trump’s comments as in line with our expectations for the price negotiation related to Novo’s GLP-1 portfolio"

YTD, up to last close, LLY up 6.1%, U.S.-listed Novo down 34.8%

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

Tradingkey
KeyAI